Regeneron drug halves muscle loss alongside semaglutide in trial
Reuters reports the combination preserved lean mass versus Novo Nordisk's semaglutide alone, a central question for incretin-based obesity care.
MH
By Maren Holt · Senior Reporter, GLP-1
Sep 30 18:06 ETSource: Reuters
The wire
- 01Reuters reports a Regeneron agent cut muscle loss by half when given with Novo Nordisk's semaglutide in a clinical trial.
- 02Muscle preservation during rapid GLP-1 weight loss is a growing concern for prescribers and a focus of combination pipelines.
- 03Full trial details, duration and functional outcomes were not laid out in the headline report; body-composition gains still need to translate into strength or function.
From the source
Read at reuters.comRegeneron drug halves muscle loss in combination with Novo's semaglutide in trial
